Related Experiment Video

Updated: Jul 17, 2025

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

8.8K

Correction to: Next‑generation PET/CT imaging in meningioma-first clinical experiences using the novel SSTR‑targeting

Marcus Unterrainer1,2, Sophie C Kunte3, Lena M Unterrainer3

  • 1Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany. Marcus.Unterrainer@med.uni-muenchen.de.

European Journal of Nuclear Medicine and Molecular Imaging
|August 29, 2023
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.1K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K

Related Experiment Videos

Last Updated: Jul 17, 2025

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

8.8K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.1K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

4.3K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
4.3K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

153
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
153

Articles linked to this work by shared authors, journal, and citation graph.

Allocation of TSPO-PET signals to cellular and extracellular compartments in dependence of blood-brain barrier disruption in experimental glioblastoma.

European journal of nuclear medicine and molecular imaging·2026

Correlation of apparent diffusion coefficient, FAP expression in IHC and [68Ga]Ga‑FAPI‑46 uptake using integrated PET/MRI in high-grade soft tissue sarcoma: initial exploratory results.

EJNMMI research·2026

Baseline body composition and early PRRT outcome in GEP-NETs: an exploratory analysis.

European journal of nuclear medicine and molecular imaging·2026

Influence of increased injected activities up 9.0 GBq [177Lu]Lu-PSMA-I&T on absorbed doses to lesions and kidneys.

EJNMMI physics·2026

Krenning score enhances integrated biomarker models for survival prediction in PRRT-treated GEP-NET: a retrospective cohort study.

Cancer imaging : the official publication of the International Cancer Imaging Society·2026

Impact of structured reporting on interpretability of PSMA PET/CT in prostate cancer staging-towards standardised clinical implementation.

European radiology experimental·2026

Differentiation of axial spondyloarthritis-related lesions from degenerative lesions on Na[18F]Fluoride PET/CT in a longitudinal dataset of patients with radiographic axial spondyloarthritis.

European journal of nuclear medicine and molecular imaging·2026

¹⁸F-sodium fluoride PET/CT as a complementary measure of osteoblastic disease burden in axial spondyloarthritis: a prospective exploratory study.

European journal of nuclear medicine and molecular imaging·2026

First-in-human dosimetry and biodistribution of [89Zr]Zr-oxine-labeled autologous leukocytes using PET/CT.

European journal of nuclear medicine and molecular imaging·2026

Diagnostic performance of multiparametric model integrating ¹⁸F-MFBG PET/CT imaging parameters and clinical factors for differentiating neuroblastoma from ganglioneuroblastoma: a preliminary study.

European journal of nuclear medicine and molecular imaging·2026

PD-L1 PET/CT imaging with 18F-BMS-986,229 and 18F-BMS-986,192 in patients with advanced-stage non-small cell lung cancer.

European journal of nuclear medicine and molecular imaging·2026

A FABulous approach to image human macrophages.

European journal of nuclear medicine and molecular imaging·2026

A Novel Sequential Regimen of Efgartigimod and Telitacicept as Fast-Acting Treatment for Impeding Crisis of MuSK-MG.

Immunity, inflammation and disease·2026

Advances in non-invasive monitoring of drug delivery for neurodegenerative disorders.

Expert review of medical devices·2026

[Retracted] (‑)‑Epicatechin protects against myocardial ischemia‑induced cardiac injury via activation of the PTEN/PI3K/AKT pathway.

Molecular medicine reports·2026

Encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the BECARE (GEM-2002) trial.

Neuro-oncology advances·2026

Advancing Membrane Technologies for Cancer Therapy and Environmental Health: Biomimetic Innovations, Smart Technologies, and Sustainable Translation.

ACS omega·2026

Rare Diseases as Engines of Biomedical Innovation: Lessons for Gene Therapy and Common Disease.

The Yale journal of biology and medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us